<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="http://medicalxpress.com/tmpl/default/css/default/feedRSS.xsl"?>
<rss version="2.0" 
	xmlns:media="http://search.yahoo.com/mrss/">
<channel>
<title>Medical Xpress: PHYSorg news tagged with: parasitic infection</title>
<link>http://medicalxpress.com/</link>
<language>en-us</language> 
<description>Medical Xpress internet news portal provides the latest news on Health and Medicine.</description>

 <item>
     <title>Resistance to visceral leishmaniasis: New mechanisms involved</title>
   	 <description>Researchers from CNRS, Université Toulouse III - Paul Sabatier and IRD have elucidated new molecular mechanisms involved in resistance to visceral leishmaniasis, a serious parasitic infection. They have shown that dectin-1 and mannose receptors participate in the protection against the parasite responsible for this infection, by triggering an inflammatory response, while the DC-SIGN receptor facilitates the penetration of the pathogen and its proliferation in macrophages. This work, conducted on both mice and humans and published on 16 May 2013 in the journal Immunity, opens new perspectives for the prevention and treatment of this disease.</description>
     <link>http://medicalxpress.com/news/2013-05-resistance-visceral-leishmaniasis-mechanisms-involved.html</link>
	 <category>Immunology</category>
	 <pubDate>Thu, 16 May 2013 11:10:01 EST</pubDate>
	 <guid isPermaLink="false">news287919687</guid>
	 
</item>
<item>
     <title>Newly described type of immune cell and T cells share similar path to maturity, according to new study</title>
   	 <description>(Medical Xpress)—Labs around the world, and a core group at Penn, have been studying recently described populations of immune cells called innate lymphoid cells (ILCs). Some researchers liken them to foot soldiers that protect boundary tissues such as the skin, the lining of the lung, and the lining of the gut from microbial onslaught. They also have shown they play a role in inflammatory disease, when the body's immune system is too active.</description>
     <link>http://medicalxpress.com/news/2013-05-newly-immune-cell-cells-similar.html</link>
	 <category>Immunology</category>
	 <pubDate>Tue, 14 May 2013 07:10:01 EST</pubDate>
	 <guid isPermaLink="false">news287733340</guid>
	 
</item>
<item>
     <title>Study discloses new test for river blindness infection</title>
   	 <description>Scientists at The Scripps Research Institute (TSRI) have found a telltale molecular marker for Onchocerciasis or &quot;river blindness,&quot; a parasitic infection that affects tens of millions of people in Africa, Latin America and other tropical regions. The newly discovered biomarker, detectable in patients' urine, is secreted by Onchocerca volvulus worms during an active infection. The biomarker could form the basis of a portable, field-ready test with significant advantages over current diagnostic methods.</description>
     <link>http://medicalxpress.com/news/2013-02-discloses-river-infection.html</link>
	 <category>Diseases, Conditions, Syndromes</category>
	 <pubDate>Mon, 25 Feb 2013 15:00:01 EST</pubDate>
	 <guid isPermaLink="false">news281008969</guid>
	 <media:thumbnail url="http://s.ph-cdn.com/newman/gfx/news/tmb/2013/studydisclos.jpg" width="90" height="90" />
</item>
<item>
     <title>New study highlights Chagas disease as a growing health and socio-economic challenge</title>
   	 <description>Today, The Lancet Infectious Diseases published a new report that examines the global economic burden of Chagas disease. In the first study of its kind, researchers measured the health and economic impact of Chagas disease and found that the total economic burden of Chagas disease matches or exceeds that of many more well-known diseases such as rotavirus, Lyme disease and cervical cancer.</description>
     <link>http://medicalxpress.com/news/2013-02-highlights-chagas-disease-health-socio-economic.html</link>
	 <category>Diseases, Conditions, Syndromes</category>
	 <pubDate>Thu, 07 Feb 2013 18:30:03 EST</pubDate>
	 <guid isPermaLink="false">news279472375</guid>
	 
</item>
<item>
     <title>Jimmy Carter: Guinea worm cases decreasing</title>
   	 <description>Guinea worm disease cases were cut to less than 600 in 2012, marking significant progress in eradicating the parasitic infection, former President Jimmy Carter said Thursday.</description>
     <link>http://medicalxpress.com/news/2013-01-jimmy-carter-guinea-worm-cases.html</link>
	 <category>Diseases, Conditions, Syndromes</category>
	 <pubDate>Thu, 17 Jan 2013 16:07:49 EST</pubDate>
	 <guid isPermaLink="false">news277661263</guid>
	 
</item>
<item>
     <title>Fighting sleep: Discovery may lead to new treatments for deadly sleeping sickness</title>
   	 <description>While its common name may make it sound almost whimsical, sleeping sickness, or African trypanosomiasis, is in reality a potentially fatal parasitic infection that has ravaged populations in sub-Saharan Africa for decades, and it continues to infect thousands of people every year.</description>
     <link>http://medicalxpress.com/news/2013-01-discovery-treatments-deadly-sickness.html</link>
	 <category>Diseases, Conditions, Syndromes</category>
	 <pubDate>Thu, 17 Jan 2013 13:10:59 EST</pubDate>
	 <guid isPermaLink="false">news277650652</guid>
	 <media:thumbnail url="http://s.ph-cdn.com/newman/gfx/news/tmb/2013/fightingslee.jpg" width="90" height="90" />
</item>
<item>
     <title>Statin drug shows promise for fighting malaria effects</title>
   	 <description>Researchers have discovered that adding lovastatin, a widely used cholesterol-lowering drug, to traditional antimalarial treatment decreases neuroinflammation and protects against cognitive impairment in a mouse model of cerebral malaria. Although there are differences between mouse models of cerebral malaria and human disease, these new findings indicate that statins are worthy of consideration in clinical trials of cerebral malaria, according to an article published in the Dec. 27 issue of PLOS Pathogens.</description>
     <link>http://medicalxpress.com/news/2012-12-statin-drug-malaria-effects.html</link>
	 <category>Diseases, Conditions, Syndromes</category>
	 <pubDate>Thu, 27 Dec 2012 17:00:03 EST</pubDate>
	 <guid isPermaLink="false">news275848796</guid>
	 
</item>
<item>
     <title>Rare human parasite found in US horse for the first time, researchers report</title>
   	 <description>(Medical Xpress)—A rare, potentially fatal species of parasite never before found in North America has been identified in a Florida horse.</description>
     <link>http://medicalxpress.com/news/2012-11-rare-human-parasite-horse.html</link>
	 <category>Diseases, Conditions, Syndromes</category>
	 <pubDate>Fri, 16 Nov 2012 07:42:17 EST</pubDate>
	 <guid isPermaLink="false">news272274106</guid>
	 
</item>
<item>
     <title>Antisense approach promising for treatment of parasitic infections</title>
   	 <description>A targeted approach to treating toxoplasmosis, a parasitic disease, shows early promise in test-tube and animal studies, where it prevented the parasites from making selected proteins. When tested in newly infected mice, it reduced the number of viable parasites by more than 90 percent, researchers from the University of Chicago Medicine report in the Proceedings of the National Academy of Sciences.</description>
     <link>http://medicalxpress.com/news/2012-08-antisense-approach-treatment-parasitic-infections.html</link>
	 <category>Medical research</category>
	 <pubDate>Mon, 13 Aug 2012 15:03:45 EST</pubDate>
	 <guid isPermaLink="false">news264088963</guid>
	 
</item>
<item>
     <title>Vaccine against black fever being tested</title>
   	 <description>After more than two decades of research, scientists are testing the first vaccine against the deadliest form of a disease that infects more than 12 million people worldwide.</description>
     <link>http://medicalxpress.com/news/2012-04-vaccine-black-fever.html</link>
	 <category>Medications</category>
	 <pubDate>Mon, 23 Apr 2012 13:30:02 EST</pubDate>
	 <guid isPermaLink="false">news254401130</guid>
	 
</item>
<item>
     <title>UGA animal vaccine may slow deadly spread of Chagas disease</title>
   	 <description>Chagas disease is the single most common cause of congestive heart failure and sudden death in the world. The devastating parasitic infection affects millions of people throughout Central and South America. But as global travel increases, it's becoming a greater threat in the United States and Europe as well.</description>
     <link>http://medicalxpress.com/news/2012-02-uga-animal-vaccine-deadly-chagas.html</link>
	 <category>Diseases, Conditions, Syndromes</category>
	 <pubDate>Thu, 16 Feb 2012 15:50:01 EST</pubDate>
	 <guid isPermaLink="false">news248628958</guid>
	 
</item>
<item>
     <title>Seizures in patients with pork tapeworm caused by Substance P</title>
   	 <description>A neuropeptide called Substance P is the cause of seizures in patients with brains infected by the pork tapeworm (Taenia solium), said Baylor College of Medicine researchers in a report that appears online in the open access journal PLoS Pathogens.</description>
     <link>http://medicalxpress.com/news/2012-02-seizures-patients-pork-tapeworm-substance.html</link>
	 <category>Diseases, Conditions, Syndromes</category>
	 <pubDate>Thu, 09 Feb 2012 17:00:12 EST</pubDate>
	 <guid isPermaLink="false">news248008658</guid>
	 
</item>
<item>
     <title>US not taking basic step to prevent toxoplasmosis in newborns, researcher contends</title>
   	 <description>North American babies who acquire toxoplasmosis infections in the womb show much higher rates of brain and eye damage than European infants with the same infection, according to new research from the Stanford University School of Medicine.</description>
     <link>http://medicalxpress.com/news/2011-10-basic-toxoplasmosis-newborns-contends.html</link>
	 <category>Diseases, Conditions, Syndromes</category>
	 <pubDate>Wed, 05 Oct 2011 17:46:48 EST</pubDate>
	 <guid isPermaLink="false">news237055580</guid>
	 
</item>
<item>
     <title>Clinical trial of malaria vaccine begins in Africa</title>
   	 <description>The vaccine, RTS,S, developed by GlaxoSmithKline (GSK) Biologicals and PATH Malaria Vaccine Initiative (MVI), is currently in phase III clinical trials and has previously reduced episodes of malaria in infants and young children by more than 50%.  The Liverpool team, in collaboration with the University College of Medicine, Malawi, are working in Blantyre over the next three years to investigate how to maximise its effectiveness when delivered through the childhood immunisation programme.</description>
     <link>http://medicalxpress.com/news/2011-05-clinical-trial-malaria-vaccine-africa.html</link>
	 <category>Medications</category>
	 <pubDate>Wed, 25 May 2011 10:55:23 EST</pubDate>
	 <guid isPermaLink="false">news225539712</guid>
	 
</item>


</channel>
</rss>
